Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes -- Ignore unavailable to you. Want to Upgrade?

To: S.C. Barnard who wrote (20004)	5/21/1998 9:25:00 AM
From: MoneyMade	Read Replies (1) \| Respond to of 34592

ADVR gives live and new hope to AIDS victims better than AZT To: BARRY ALLEN (40 ) From: BARRY ALLEN Wednesday, May 20 1998 6:54PM ET Reply # of 58 From our friends at AOL.............. Subject: Re: Spoke to American Society for Microbiology Date: Mon, May 18, 1998 20:20 EDT From: HillSave Message-id: <1998051900200800.UAA12006@ladder01.news.aol.com> Jake, tried to reach you on silicon but couldn't. I've been an investor in ADVR for 5 years. I thought you should hear what I found out today. Out of 750 presentors at the annual meeting and 2700 poster presentations, ADVR was selected to be highlighted on ASM web page because "They thought it was one of the most news worthy presentors and one of the most exciting medical breakthroughs." I also found out that USA today and CNN are both covering the meeting. I took it upon myself to fax the medical news room a copy of the Web page about ADVR. If you want to E-mail me please reach me at Hillsave@webtv.com. For you you people waiting to jump in don't wait to long. We are on a roll........... **********************************

To: S.C. Barnard who wrote (20004)	5/21/1998 9:25:00 AM
From: Leman	Read Replies (1) \| Respond to of 34592

HYALF in Canadian newspapers today new cancer cream replaces $250 surgical treatment

To: S.C. Barnard who wrote (20004)	5/21/1998 9:29:00 AM
From: Leman	Respond to of 34592

SAN FRANCISCO, Feb. 23 /PRNewswire/ -- Genesis Merchant Group Securities initiated coverage of Gene Logic Inc., (Nasdaq: GLGC) with a buy rating and set a 12-month price target of $13.50 per share. Genesis analyst Deepa Pakianathan noted that Gene Logic, which has developed a unique suite of proprietary technologies to measure gene expression and gene regulation, currently has three alliances potentially worth over $200 million in total: Procter and Gamble (NYSE: PG), Japan Tobacco, and Akzo Nobel/Organon. Measuring gene expression is one way to utilize genomic information to identify drug targets. In addition, Pakianathan noted that the company is expected to sign at least two additional partnerships in 1998 and two more in 1999, all of which should include subscriptions to proprietary databases and to non-exclusive database products. "Gene Logic has promising technology that we believe can be successfully used in the evolution and application of genomics in drug discovery. The successful implementation of the Flow-thru Chip, accomplishment of milestones to trigger payments from partners, and the signing of additional alliances should drive the company's stock price towards our target," said Pakianathan. (NOTE: This valuation of Gene Logic does not include its Bioinformatics capability and its OPM technology, both of which could add significant upside value going forward.) SOURCE Genesis Merchant Group Securities /CONTACT: Deepa Pakianathan of Genesis Merchant Group Securities, 415-677-1500/ /Web site: sternco.com (GLGC)